PainReform Ltd. provided a further update related to the manufacturing process of clinical batches for PRF-110. As previously announced, the company implemented additional enhancements to manufacturing process for PRF-110 expected to improve the efficiency and scalability of manufacturing. The company have since encountered issues in the manufacturing process, which will result in a delay in the commencement of planned Phase 3 trial.

Company is moving aggressively on plans and expect to report further updates as it relates to the expected start of the clinical study as soon as practical. Overall, Company remain highly encouraged by the outlook for the business based on the success of prior Phase 2 proof-of-concept clinical study. Assuming Phase 3 trial is successful, company believe PRF-110 has the potential to become standard-of-care within the $12 billion post-operative pain treatment market and represents a highly attractive alternative to systemic opioids.